Cardiac Resynchronization Therapy Market Report 2026

The cardiac resynchronization therapy market size has grown strongly in recent years. It will grow from $6.72 billion in 2025 to $7.18 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing prevalence of heart failure, improved awareness of ventricular dyssynchrony, expansion of cardiac device implantation centers, advancements in pacemaker technology, growing clinical evidence supporting crt benefits.

The cardiac resynchronization therapy market size is expected to see strong growth in the next few years. It will grow to $8.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to increasing demand for next-generation crt systems, rising adoption of remote cardiac device management, expansion of aging population with heart failure, growing focus on therapy optimization, increasing investments in cardiac rhythm management technologies. Major trends in the forecast period include increasing adoption of advanced crt devices, rising use of personalized device programming, growing integration of remote device monitoring, expansion of minimally invasive implantation techniques, enhanced focus on patient outcome optimization.

The rising prevalence of cardiovascular diseases is anticipated to drive the growth of the cardiac resynchronization therapy market in the coming years. Cardiovascular diseases (CVD) encompass a group of conditions that impact the heart and blood vessels. The incidence of cardiovascular disease is increasing due to multiple factors, including aging populations, unhealthy lifestyles, higher tobacco consumption, sedentary behavior, and poor dietary habits. Cardiac resynchronization therapy (CRT) supports the treatment of cardiovascular conditions, such as heart failure, by enhancing the coordination of the heart's contractions through the delivery of synchronized electrical impulses. For example, in September 2024, data published by the Minnesota Department of Health, a US-based state health agency, indicated that nearly 30% of adults in Minnesota had high blood pressure in 2023, amounting to approximately 1.4 million individuals. In 2022, hypertensive diseases were the underlying or contributing cause of death for 14,225 residents, representing around 28% of all deaths in the state. As a result, the increasing prevalence of cardiovascular diseases is fueling the growth of the cardiac resynchronization therapy market.

The rising healthcare expenditure is anticipated to drive the growth of the cardiac resynchronization therapy market in the coming years. Healthcare expenditure refers to the total amount of money allocated to healthcare goods and services over a specific period, typically measured at a national or institutional level. Investment in healthcare can facilitate research and development in cardiac resynchronization therapy, leading to technological advancements, enhanced access to therapy, and a more holistic approach to individual health and healthcare systems. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency that manages the Medicare and Medicaid programs, U.S. healthcare spending in 2023 rose by 7.5%, reaching $4.9 trillion, or approximately $14,570 per person. Consequently, the increasing healthcare expenditure is supporting the growth of the cardiac resynchronization therapy market.

Major companies operating in the cardiac resynchronization therapy market are concentrating on developing implantable devices such as cardiac resynchronization therapy device launches to enhance real-time hemodynamic optimization and improve patient-specific cardiac pacing outcomes. Cardiac resynchronization therapy (CRT) device launch refers to the formal introduction of an implantable medical device designed to improve the coordination of heart chamber contractions in patients with heart failure. For example, in February 2024, MicroPort Scientific Corporation, a China-based medical device company, launched the GALI SonR cardiac resynchronization therapy and defibrillation device (CRT-D), an implantable device, along with the Navigo 4LV left ventricular pacing leads in Japan. This is the first and only CRT hemodynamic sensor designed to automatically optimize patients once a week and, more importantly, while the patient is active, enabling real-life optimization. The clinically validated SonR algorithm has demonstrated a 35% reduction in the risk of heart failure hospitalization and will also contribute to ensuring the well-being and safety of CRT-D patients.

Major companies operating in the cardiac resynchronization therapy market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co KG, MicroPort Scientific Corporation, LivaNova PLC, Lepu Medical Technology Beijing Co Ltd, Osypka Medical GmbH, EBR Systems Inc, Japan Lifeline Co Ltd, CCC Medical Devices, Shree Pacetronix Ltd, BPL Medical Technologies, Medico Srl, Pacetronix, Lepu Healthcare, Blue Cross Bio Medical, Cardiac Science International, Beijing Jinshi Medical, Suzhou Medical Instrument Factory.

North America was the largest region in the cardiac resynchronization therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac resynchronization therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac resynchronization therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cardiac resynchronization therapy market by increasing costs of imported electronic components, leads, batteries, semiconductors, and device housings used in CRT pacemakers and defibrillators. Hospitals and cardiac care centers in North America and Europe are most affected due to dependence on imported device components, while Asia-Pacific faces cost pressures on device manufacturing and distribution. These tariffs are increasing device prices and slowing implantation rates in some regions. However, they are also promoting local device assembly, regional supplier development, and increased investment in domestic cardiac rhythm management manufacturing capabilities.

The cardiac resynchronization therapy market research report is one of a series of new reports that provides cardiac resynchronization therapy market statistics, including cardiac resynchronization therapy industry global market size, regional shares, competitors with a cardiac resynchronization therapy market share, detailed cardiac resynchronization therapy market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac resynchronization therapy industry. This cardiac resynchronization therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiac resynchronization therapy (CRT) is a treatment for heart failure that helps coordinate the contractions of the heart's ventricles. CRT uses a biventricular pacemaker to deliver electrical impulses to the heart muscle, enabling the ventricles to beat in a more synchronized way. It can improve heart failure symptoms, such as shortness of breath and fatigue, and enhance the overall function of the heart.

The primary types of cardiac resynchronization therapy are cardiac resynchronization therapy (CRT)-defibrillator and cardiac resynchronization therapy (CRT)-pacemaker. A CRT defibrillator is a medical device that helps control the heartbeat and delivers electrical shocks if the heart beats irregularly. These devices are utilized for patients aged under 44 years, 45-64 years, 65-84 years, and over 85 years by hospitals, cardiac care centers, and ambulatory surgical centers.

The cardiac resynchronization therapy market consists of revenues earned by entities by providing services such as patient evaluation and diagnosis, device implantation procedures, device programming, follow-up care, management of complications, patient education, and collaborative care involving a multidisciplinary team. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac resynchronization therapy market also includes sales of pacemakers or defibrillators, leads, programmers, accessories, diagnostic tools, patient monitoring devices, and educational materials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.